EYEPOINT PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.59 USD | -2.94% |
|
-14.06% | -58.61% |
Presentation Operator MessageOperator (Operator)Welcome to the EyePoint Third Quarter 2022 Fin...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Companyâs other products include YUTIQ, and DEXYCU.
Sector
Pharmaceuticals
Calendar
20/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.88
USD
Average target price
39.11
USD
Spread / Average Target
+295.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.61% | 515M | |
| +42.49% | 748B | |
| +33.99% | 598B | |
| -5.79% | 356B | |
| +18.05% | 325B | |
| +4.56% | 283B | |
| +17.06% | 245B | |
| +9.08% | 211B | |
| -4.09% | 209B | |
| +1.89% | 166B |
- Stock Market
- Equities
- EYPT Stock
- News EyePoint Pharmaceuticals, Inc.
- Transcript : EyePoint Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 02, 2022
